Allergy Therapeutics’ (LON:AGY) finance director Ian Postlethwaite is to leave to take another post elsewhere.
He will stay in the position for up to six months while the hay fever vaccine group finds a replacement.
Peter Jensen, Allergy Therapeutics’ chairman said: "Ian has been the Finance Director for 14 years and a significant contributor to the success of the company.
“During this time Allergy Therapeutics has listed on AIM, achieved a number of financial goals including two fund raisings in 2015 to support the Company's clinical and other development plans, and has growing revenues from products on sale in Europe.
“Ian leaves the company in the strongest position it has ever been in, in terms of sales, cash balance and growth potential.”